profit from every PLN 100 of sales.
PLN 0PLN 100
Diagnostyka
PLN 154.00+0.59% today
-9.4% in 1 year
1-year low PLN 146.101-year high PLN 202.60
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay PLN 20.66 for every PLN 1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Diagnostyka sold, what it kept, and what it did with the cash.
Sales went from PLN 1.44 billion in 2022 to PLN 2.41 billion in 2025, with PLN 252 million of profit last year.
SalesProfit
Diagnostyka handed back 32% of the cash it generated last year.
PLN 112M
Free cash flow 2025PLN 347M
Bought back its own shares–
Paid as dividendsPLN 112M
Cash vs. debtPLN 18M vs. PLN 1.1B
Diagnostyka vs. similar companies
Diagnostyka grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from PLN 100 of sales | Sales growth a year | Price per PLN 1 of profit |
|---|---|---|---|
| Diagnostyka | 20.7× · Fair price | ||
 Thermo Fisher Scientific | 38.7× · Expensive | ||
 Danaher | 45.2× · Expensive | ||
 Waters | 141.4× · Very expensive | ||
 WuXi AppTec | 27.1× · Fair price |
AI analysis
An AI analyst reads Diagnostyka's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of PLN | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,436 | 1,588 | 1,950 | 2,410 | |
| 936 | 1,033 | 1,530 | 1,905 | |
| 252 | 233 | 337 | 384 | |
| 381 | 375 | 510 | 588 | |
| 167 | 123 | 223 | 252 | |
| 4.96 | 3.66 | 6.62 | 7.45 | |
| 65.2% | 65.1% | 78.5% | 79.0% | |
| 17.6% | 14.7% | 17.3% | 15.9% | |
| 11.7% | 7.8% | 11.5% | 10.4% |
Balance sheet
| In millions of PLN | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,197 | 1,398 | 1,718 | 2,070 |
| Cash | 91 | 95 | 41 | 18 |
| Total debt | 721 | 850 | 969 | 1,081 |
| Total liabilities | 878 | 1,062 | 1,285 | 1,522 |
| 313 | 325 | 419 | 528 | |
| 34 | 34 | 34 | 34 | |
| 20.0% | 15.7% | 20.3% | 19.4% | |
| 53.6% | 38.0% | 53.3% | 47.6% |
Cash flow
| In millions of PLN | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 284 | 336 | 415 | 552 | |
| 89 | 81 | 133 | 205 | |
| 195 | 255 | 283 | 347 | |
| Dividends paid | 294 | 112 | 106 | 112 |
| – | – | – | – | |
| 2 | 2 | 4 | 8 |
Valuation
- 20.7×
- –
- 1.42
- 11.2×
- 2.2×
- 15.0×
- 10.7×
- 6.7%
- 4.8%
- 2.1%
Profitability
- 79.0%
- 15.9%
- 10.4%
- –
- 19.4%
- 18.9%
- –
- –
- –
- –
Growth
- +18.9%
- +14.5%
- –
- –
- +0.0%
Financial health
- 1.8×
- 2.05
- –
- 5.6×
- 0.73
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 9%of 952
Top 33%of 883
Top 35%of 576
Top 31%of 870
Top 14%of 985
2.1%of the share price, paid each year
On $1,000 invested$21a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
44.4% of its profit
Room to growStretchedMore than it earns: 32.2%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
5/7Passes 5 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
68Pass
Benjamin Graham
44No pass
Philip Fisher
78Pass
Peter Lynch
63Pass
Joel Greenblatt
47No pass
Charlie Munger
68Pass
Terry Smith
72Pass
Questions about Diagnostyka
Is Diagnostyka a good stock to buy?
A solid business at a fair price. 5 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Diagnostyka AI analysis
What does Diagnostyka do?
Diagnostyka S.A. provides diagnostic services in Poland. The company operates as a medical laboratory, which offers services, such as ultrasound, X-ray, computed tomography, and magnetic resonance imaging. It is in Diagnostics & Research, based in Kraków, Poland, with 8,645 employees.
Does Diagnostyka pay a dividend?
Yes. At today's price the dividend is 2.1% a year, about 44% of its yearly profit. In 2025 it paid out PLN 112 million in dividends.
Is Diagnostyka stock halal?
Yes. Diagnostyka passes our halal screen: its business is permitted and its debt is 21% of its market value, under the 30% limit. How we check
How has Diagnostyka stock done over the past year?
Down 9.4% over the past twelve months, to PLN 154.00. It traded between PLN 146.10 and PLN 202.60 and is 24.0% below its high.
Who are Diagnostyka's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Danaher, Waters and WuXi AppTec. The peers table on this page compares their profit, growth and price with Diagnostyka's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.